Insider Filing Note: The director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Jason Aryeh Sold 18,479 Shares

November 25, 2016 - By Marie Mckinney

Insider Filing Note: The director of Ligand Pharmaceuticals Inc. (NASDAQ:LGND), Jason Aryeh Sold 18,479 Shares

Jason Aryeh Insider Sell

It was disclosed in a legal document that has been filled with the U.S. Security & Exchange Commission that Jason Aryeh, who works for Ligand Pharmaceuticals Inc, and serves as director completed an insider trade on 25/11/2016. He sold 18,479 shares of the public firm estimated based on $107.3 U.S. Dollars per share. As shown in the public document available at the SEC website here, the aggregate amount of the trade was $1,983,072 U.S. Dollars. He also unloaded 6,330 shares with value $666,419 USD in the last 30 days. Jason Aryeh owns 1.20% of the -company’s market cap or 249,882 shares.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Ratings Coverage

Out of 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 80% are positive. $160 is the highest target while $140 is the lowest. The $150.75 average target is 41.68% above today’s ($106.4) stock price. Ligand Pharmaceuticals has been the topic of 12 analyst reports since September 3, 2015 according to StockzIntelligence Inc. TH Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rating on Thursday, November 19. TH Capital has “Buy” rating and $144 price target. Roth Capital maintained the stock with “Buy” rating in Monday, September 21 report. The firm has “Buy” rating by TH Capital given on Friday, December 18. Roth Capital maintained the stock with “Buy” rating in Thursday, November 19 report. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Friday, December 18. Roth Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Friday, March 11 with “Buy” rating. TH Capital maintained the stock with “Buy” rating in Wednesday, September 30 report. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Thursday, September 3. H.C. Wainwright maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) rating on Wednesday, October 5. H.C. Wainwright has “Buy” rating and $160 price target. The rating was initiated by Stephens with “Overweight” on Wednesday, April 13.

Insitutional Activity: The institutional sentiment decreased to 1.08 in 2016 Q2. Its down 0.18, from 1.26 in 2016Q1. The ratio turned negative, as 27 funds sold all Ligand Pharmaceuticals Inc. shares owned while 81 reduced positions. 38 funds bought stakes while 98 increased positions. They now own 22.63 million shares or 4.24% less from 23.63 million shares in 2016Q1.

Paradigm Asset Mgmt Lc holds 5,753 shares or 0% of its portfolio. Proshare Advsrs Ltd Co accumulated 0.03% or 18,249 shares. Hanseatic Mngmt Ser Inc holds 0.35% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 7,819 shares. Baker Bros Advsr L P holds 0.09% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 73,386 shares. Suffolk Capital Ltd Liability reported 20,457 shares or 0.31% of all its holdings. The Ohio-based Fifth Third Bank has invested 0.01% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Moreover, Stifel has 0% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 2,159 shares. Tompkins holds 35 shares or 0% of its portfolio. Moreover, Eqis has 0.1% invested in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) for 12,593 shares. Stephens Inc Ar holds 0% or 701 shares in its portfolio. Cornerstone Cap Management Ltd Liability Co has invested 0% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). United Services Automobile Association accumulated 0.01% or 30,770 shares. Employees Retirement Association Of Colorado has invested 0.01% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Envestnet Asset Inc has 5,084 shares for 0% of their US portfolio. Alpine Woods Capital Investors Ltd Com has 0.02% invested in the company for 2,217 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 7 selling transactions for $5.70 million net activity. 1,666 shares with value of $175,597 were sold by KOZARICH JOHN W on Thursday, September 1. Another trade for 12,500 shares valued at $1.53M was made by FOEHR MATTHEW W on Friday, August 5. HIGGINS JOHN L sold 3,000 shares worth $352,020. Berkman Charles S sold $2.72 million worth of stock. On Wednesday, November 16 Aryeh Jason sold $666,419 worth of the stock or 6,330 shares.

About 144,372 shares traded hands. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has declined 17.94% since April 22, 2016 and is downtrending. It has underperformed by 23.35% the S&P500.

Ligand Pharmaceuticals Incorporated is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company has a market cap of $2.23 billion. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It currently has negative earnings. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development.

According to Zacks Investment Research, “Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men’s and women’s hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand’s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.”

Analysts await Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to report earnings on February, 8. They expect $0.67 earnings per share, up 28.85% or $0.15 from last year’s $0.52 per share. LGND’s profit will be $14.04M for 39.70 P/E if the $0.67 EPS becomes a reality. After $0.03 actual earnings per share reported by Ligand Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 2,133.33% EPS growth.

More notable recent Ligand Pharmaceuticals Inc. (NASDAQ:LGND) news were published by: Fool.com which released: “Here’s Why Ligand Pharmaceuticals Inc Is Plunging Today” on September 27, 2016, also Prnewswire.com with their article: “LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated ..” published on November 22, 2016, Businesswire.com published: “Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been ..” on November 18, 2016. More interesting news about Ligand Pharmaceuticals Inc. (NASDAQ:LGND) were released by: Fool.com and their article: “Licensing Agreements Drive Ligand Pharmaceuticals Inc. 13% Higher in July” published on August 08, 2016 as well as Prnewswire.com‘s news article titled: “Ligand Pharmaceuticals Inc. Investigated For Securities Fraud By Block ..” with publication date: November 16, 2016.

LGND Company Profile

Ligand Pharmaceuticals Incorporated (Ligand), incorporated on September 28, 1987, is a biopharmaceutical firm that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Firm employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. It has have partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 different programs under license with it are in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others. The Company’s partners have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease and kidney disease, among others. The Firm is developing a small molecule glucagon receptor antagonist for the treatment of Type II diabetes mellitus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>